A Three Part, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of Inhaled and Intravenous GSK2862277 in Healthy Volunteers
Latest Information Update: 07 Sep 2023
At a glance
- Drugs GSK 2862277 (Primary) ; GSK 2862277 (Primary)
- Indications Respiration disorders
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 30 Nov 2013 New trial record
- 22 Nov 2013 Status changed from recruiting to completed.